KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Current Leases (2020 - 2025)

Adaptive Biotechnologies' Current Leases history spans 6 years, with the latest figure at $8.9 million for Q4 2025.

  • For Q4 2025, Current Leases fell 12.88% year-over-year to $8.9 million; the TTM value through Dec 2025 reached $8.9 million, down 12.88%, while the annual FY2025 figure was $8.9 million, 12.88% down from the prior year.
  • Current Leases for Q4 2025 was $8.9 million at Adaptive Biotechnologies, down from $9.4 million in the prior quarter.
  • Across five years, Current Leases topped out at $10.5 million in Q1 2025 and bottomed at $4.3 million in Q1 2021.
  • The 5-year median for Current Leases is $9.3 million (2023), against an average of $8.5 million.
  • The largest annual shift saw Current Leases skyrocketed 186.82% in 2021 before it dropped 12.88% in 2025.
  • A 5-year view of Current Leases shows it stood at $5.1 million in 2021, then surged by 82.59% to $9.2 million in 2022, then grew by 1.67% to $9.4 million in 2023, then increased by 9.11% to $10.2 million in 2024, then decreased by 12.88% to $8.9 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Current Leases are $8.9 million (Q4 2025), $9.4 million (Q3 2025), and $10.0 million (Q2 2025).